Meeting Banner
Abstract #0018

GluCEST imaging in a primate model of Alzheimers disease

Julien Flament 1,2 , Charlotte Gary 2,3 , James Koch 2,4 , Fabien Pifferi 5 , Emmanuel Comoy 6 , Jean-Luc Picq 7 , Julien Valette 2,3 , and Marc Dhenain 2,3

1 INSERM US27, CRC-MIRCen, Fontenay-aux-Roses, France, 2 CEA/DSV/I2BM/MIRCen, Fontenay-aux-Roses, France, 3 CNRS URA 2210, Fontenay-aux-Roses, France, 4 Department of Psychology, University of Wisconsin, Oshkosh, WI, United States, 5 CNRS-MNHN UMR 7179, Brunoy, France, 6 CEA/DSV/iMETI/SEPIA, Fontenay-aux-Roses, France, 7 EA 2027, Universit Paris 8, Saint-Denis, France

This study describes the possibility to image glutamate concentration alterations using gluCEST. Injection of brain homogenates of Alzheimers disease (AD) patients in susceptible mice can induce or accelerate the pathology, suggesting a prion-like mechanism. Here, two groups of mouse lemur primates were injected with brain homogenate of either AD (n=4) or age-matched control patients (n=3). They were characterized by MRS, showing modifications in metabolic profile, especially a decrease in glutamate concentration (-16.5%). GluCEST images showed a decrease of gluCEST contrast (-17.6%) reflecting glutamate concentration variation. These results suggest that glutamate level could be a surrogate marker of disease progression.

This abstract and the presentation materials are available to members only; a login is required.

Join Here